Clinical Trials · NCT02607865
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 1,864
- Start date
- Feb 2016
- Locations
- 242 sites, 15 countries
- Primary endpoint
- Change in HbA1c: Week 26